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Abstract
Introduction: Melatonin was found to inhibit forskolin-stimulated oxytocin (OT) and vasopressin (VP) release in vitro. The purpose of the 
present investigation was to evaluate the contribution of the cyclic 3’,5’-adenosine monophosphate/protein kinase A (cAMP/PKA) signalling 
pathway in melatonin-dependent inhibition of OT and VP secretion from the rat hypothalamo-neurohypophysial (H-NH) system in vitro.
Material and methods: The H-NH explants were placed in 1 ml of normal Krebs-Ringer (nK-R) buffer and first preincubated for 30 min 
in control buffer or in the presence of PKA inhibitor, i.e. cAMPS-Rp or H-89. Next, they were incubated in nK-R buffer {fluid F1} and then 
in buffer as F1 enriched with melatonin (10–9 M or 10–7 M) and/or PKA activator, i.e. cAMP analogue (8-Br-cAMP), or their vehicles {fluid 
F2}. After 20 min of incubation in fluid F1 and then F2, the media were collected and frozen, to be assayed for OT and VP by the RIA.
Results: 8-Br-cAMP increased OT and VP secretion when the H-NH explants were preincubated in control medium, while PKA inhibitors 
eliminated its stimulatory effect on OT and VP release. Melatonin (10–7 M) diminished basal OT and VP output from the H-NH system, 
and inhibited (at both concentrations studied) the cAMP analogue-stimulated release of both neurohormones under control conditions. 
The effect of melatonin on OT and VP release was completely blocked when cAMPS-Rp, but not H-89, was used to disrupt the cAMP/ 
/PKA pathway.
Conclusions: Melatonin employs the cAMP/PKA signalling pathway to inhibit OT and VP secretion from the rat H-NH system; nonethe-
less, other cAMP-mediated mechanisms are not excluded. (Endokrynol Pol 2018; 69 (5): 560–566)
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Streszczenie
Wstęp: Melatonina hamuje pobudzane forskoliną wydzielanie oksytocyny (OT) i wazopresyny (VP) in vitro. Celem badań było wyka-
zanie udziału szlaku sygnałowego 3’,5’-cykliczny adenozynomonofosforan/kinaza białkowa A (cAMP/PKA) w zależnym od melatoniny 
hamowaniu wydzielania OT i VP z układu podwzgórze–część nerwowa przysadki szczura (H-NH) in vitro.
Materiał i metody: Po wyosobnieniu z mózgu, układ H-NH umieszczano w probówkach zawierających 1 ml normalnego buforu Krebsa-
-Ringera (nK-R). Układ H-NH podlegał początkowo preinkubacji, przez 30 min, w buforze kontrolnym (nK-R) lub zawierającym inhibitor 
PKA, tj. cAMPS-Rp lub H-89. Następnie, inkubacja przebiegała w buforze nK-R {płyn F1}, a potem w buforze jak F1 wzbogaconym 
o melatoninę (10–9 M lub 10–7 M) i/lub aktywator PKA, tj. analog cAMP (8-Br-cAMP) lub ich rozpuszczalniki (0.1% etanol lub DMSO) {płyn 
F2}. Po inkubacji układu H-NH w każdym z roztworów (F1 i F2) przez 20 min płyn inkubacyjny pobierano i natychmiast zamrażano do 
czasu oznaczenia w zebranych próbkach zawartości OT i VP metodą RIA.
Wyniki: 8-Br-cAMP zwiększał wydzielanie OT i VP z układu H-NH gdy preinkubacja tego układu odbywała się w medium kontrolnym, 
podczas gdy inhibitory PKA (cAMPS-Rp oraz H-89) eliminowały wpływ analogu cAMP na wyrzut OT i VP. Melatonina (10–7 M) zmniejszała 
podstawowe wydzielanie OT i VP z układu H-NH, jak również hamowała (w obydwu badanych stężeniach) pobudzane przez 8-Br-cAMP 
wydzielanie obydwu neurohormonów w warunkach kontrolnych. Gdy w celu przerwania szlaku cAMP/PKA zastosowano cAMPS-Rp, 
ale nie H-89, hamujący wpływ melatoniny na wyrzut OT i VP do płynu inkubacyjnego był całkowicie zniesiony.
Wnioski: Melatonina wykorzystuje szlak sygnałowy cAMP/PKA do hamowania wydzielania OT i VP z układu H-NH szczura, niemniej, 
nie można wykluczyć udziału w tym procesie innych zależnych od cAMP mechanizmów. (Endokrynol Pol 2018; 69 (5): 560–566)
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To disrupt the cAMP/PKA signalling pathway, 
several pharmacological inhibitors of PKA can be 
employed. Two of them, i.e. cAMPS-Rp (which acts 
as a competitive cAMP antagonist which inhibits PKA 
activation) [19, 20] and H-89 (a potent inhibitor of PKA 
and some other kinases) [20–22], have been shown to 
antagonise the effects of cAMP/PKA stimulators, such 
as forskolin [21, 23, 24], pituitary adenylate cyclase-
activating polypeptide (PACAP) [25–27], or cAMP 
analogue(s) [25–29]. These two PKA inhibitors have 
also been used frequently when studying the role of 
the cAMP/PKA-dependent signal transduction cascade 
in CNS function and behaviour [5, 22, 30–33]. There-
fore, the purpose of the present investigation was to 
evaluate the contribution of the cAMP/PKA signalling 
pathway in melatonin-dependent inhibition of OT 
and VP secretion from an isolated rat hypothalamo-
neurohypophysial system, which has not been studied 
yet. To achieve this aim, the study employs the PKA 
inhibitors (cAMPS-Rp and H-89) and the PKA activator, 
i.e. cAMP analogue (8-Br-cAMP).
Material and methods
Animals
Adult male Wistar rats, weighing 260–360 g, from the 
breeding stock of the Medical University of Lodz, Po-
land, were housed in quarters with controlled tempera-
ture (22 ± 1°C), constant humidity, and regulated light/ 
/dark (L:D) cycles (12L/12D; light from 06.00 to 18.00 h). 
The animals had free access to commercial pelleted food 
(LSM, Bacutil, Poland) and tap water.
Compounds and reagents
Melatonin (N-acetyl-5-methoxytryptamine) and 
dimethyl sulfoxide (DMSO) were purchased from 
Sigma-Aldrich Chemie GmbH. 8-Br-cAMP (8-Bro-
moadenosine-3’,5’-cyclic monophosphate) (cAMP 
analogue; activator of the cAMP-dependent PKA), 
H-89 (N-[2-[[(3-(4-Bromophenyl)-2-propenyl]amino]
ethyl]-5-isoquinolinesulfonamide dihydrochloride) (an 
inhibitor of PKA and some other kinases) and cAMPS- 
-Rp ([R]-Adenosine, cyclic 3’,5’-[hydrogen phosphoro-
thioate] triethylammonium) (a potent cAMP antago-
nist that inhibits PKA activation) were obtained from 
Tocris Bioscience. Synthetic OT (Oxytocin synth.) and 
VP (Vasopressin synth.), used for iodination with 125I 
and for preparation of the standard curve, came from 
Peninsula Laboratories Europe Ltd. 
Experimental procedure
On each day of the experiment, the rats were de-
capitated between 9:00 and 10:10 a.m. To obtain the 
hypothalamo-neurohypophysial (H-NH) system, the 
Introduction
Melatonin affects the function of many organs and 
cells, mainly via membrane MT1 and MT2 receptors, 
which belong to the G-protein-coupled receptor (GP-
CRs) superfamily [1–3]. Together with ligand-gated 
ion channels and intracellular mechanisms, GPCRs are 
known to be engaged in the stimulation of magnocel-
lular neuron activity and the secretion of neurohypo-
physial hormones [4, 5]. Recent studies have shown 
that a subtype MT1 membrane receptor mediates the 
inhibitory impact exerted by melatonin on vasopressin 
(VP) [6] and oxytocin (OT) [7] secretion from the rat 
hypothalamo-neurohypophysial system.
Activation of the MT1 receptor by melatonin results 
in induction of two parallel intracellular pathways [2, 8]. 
One of them engages adenylyl cyclase (AC) and Gi 
proteins that mediate the inhibition of the cyclic 
3’,5’-adenosine monophosphate (cAMP)-dependent 
signal transduction pathway, including inhibition 
of protein kinase A (PKA) activity (i.e. cAMP/PKA 
pathway) and the nuclear factor — cAMP response 
element-binding protein (CREB) phosphorylation. 
The MT1 receptor can also couple to Gq/11 proteins, 
which induces a phospholipase C (PLC)-dependent 
signalling pathway, with intensification of phospho-
inositide turnover and stimulation of diacylglycerol 
(DAG) and inositol triphosphate (IP3) formation; this 
results in protein kinase C (PKC) activation (i.e. DAG/ 
/PKC pathway) and greater cytosolic free calcium ion 
accumulation [2, 3, 8–10].
Melatonin has been shown to inhibit the elevation 
in cAMP accumulation induced by forskolin (forskolin 
strongly activates AC and increases cAMP production) 
in the rat pituitary [10, 11]. In mammals, cAMP exerts 
its effects through a few direct intracellular targets, i.e. 
cAMP-dependent PKA, the exchange proteins directly 
activated by cAMP (EPACs), and cyclic nucleotide-
gated cation channels (CNGCs) [12–14]. It has been 
found that 8-Br-cAMP, a membrane-permeable cAMP 
analogue with increased hydrolytical stability, is 
a strong activator of cAMP-dependent PKA [15] and 
is able to stimulate OT and VP release in vitro [16]. 
Moreover, it is known that the transcription of VP 
gene in the rat hypothalamus is regulated by CREB: 
a cAMP-dependent transcription factor [17]. Previous in 
vitro studies have shown that melatonin significantly 
inhibits forskolin-stimulated OT and VP output from 
isolated rat hypothalamo-neurohypophysial explants 
when used at physiological concentration in rat blood 
(i.e. 10–9 M) and above (10–7 M), i.e. close to its level in 
the cerebrospinal fluid [18]; this observation suggests 
that cAMP-mediated mechanism(s) play a role in the 
influence of melatonin on OT and VP release.
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brain and the pituitary with intact pituitary stalk were 
thoroughly removed from the skull, and then a block 
of hypothalamic tissue was rapidly dissected from 
the brain, as described previously [34]. Such explant 
contained the hypothalamic suprachiasmatic (SCN), 
supraoptic (SON), and paraventricular (PVN) nuclei 
with intact neuronal projections to the neurohypo-
physis [34]. Each explant of the H-NH system was im-
mediately placed in a tube containing 1 mL of normal 
Krebs-Ringer (nK-R) buffer heated in a water bath to 
37°C; the content and parameters of nK-R buffer have 
been described previously [6, 7, 34]. Additionally, to 
each tube where one H-NH explant was incubated, 
a mixture of 95% O2 and 5% CO2 was continuously 
delivered. At the beginning of the experiment, to stabi-
lise the OT and VP secretion into the buffer, the H-NH 
explants were equilibrated for 80 min in 1 mL of nK-R 
buffer and these samples were discarded. Afterwards, 
the explants were first preincubated for 30 min in 
1 mL of nK-R buffer (control — series A), nK-R buffer 
enriched with cAMPS-Rp (series B), or nK-R buffer 
enriched with H-89 (series C). Both PKA inhibitors, i.e. 
cAMPS-Rp and H-89, were given at a frequently-used 
concentration of 10 μM for PKA inhibition. 
Immediately after the preincubation period, the 
explants were incubated for 20 min in 1 mL of nK-R 
buffer {fluid F1} and then in 1 mL of nK-R buffer en-
riched with the appropriate substances {fluid F2} for 
a further 20 min. In each series (A-C), seven different 
groups of formulation were used for fluid F2: Group 
1 — melatonin vehicle (VEH — 0.1% ethanol; n: num-
ber of samples per group, n = 7–8), Group 2 — 10–7 M 
melatonin (10–7 M MT; n = 6–7), Group 3 — 10–9 M me-
latonin (10–9 M MT; n = 6–7), Group 4 — a solvent of 
8-Br-cAMP (0.1% DMSO; n = 6–8), Group 5 — 10-5 M 
8-Br-cAMP (n = 6–8), Group 6 — 8-Br-cAMP & 10–7 M 
MT (n = 6–8), and Group 7 — 8-Br-cAMP & 10–9 M MT 
(n = 6–8). The melatonin concentrations, i.e. 10–7 M 
and 10–9 M, were selected on the basis of the results of 
previous in vitro studies. After each 20-min incubation 
period, the media (fluids F1 and F2) were aspirated and 
immediately stored at –20°C, to be later assayed for OT 
and VP by the radioimmunoassay (RIA). To determine 
the in vitro release of OT and VP, a F2/F1 ratio was cal-
culated for each H-NH explant, because the quantity 
of neurohypophysial hormone secreted into the buffer 
differs greatly, within one experimental group, from 
one H-NH explant to the other.
All series of the experiment were performed be-
tween 09.00 and 11.50 a.m. This timing was necessary 
because the expression of MT1 receptor mRNA and 
melatonin binding in the rat pars tuberalis and SCN 
are raised during daytime [35], and because the H-NH 
system is responsive to exogenous melatonin during 
this period [36]. The experiments were performed with 
the approval (No. 75/ŁB 583/2011) of the Local Commis-
sion of Ethics for Animal Care.
Radioimmunoassay of OT and VP
The concentration of OT and VP in the incubation 
medium was determined for each sample in duplicate, 
using a double-antibody RIA [37]. Iodination of OT and 
VP with 125I was executed by the chloramine-T method. 
Anti-OT and anti-VP antibodies were raised in rabbits, 
and their specification was given earlier [6, 7]. The 
anti-OT antibody titre was 1:80,000 (final dilution). The 
sensitivity of the OT assay was 2.55 pg per tube, and 
intra-assay coefficient of variation (CV), determined 
for several points of the standard curve, was less than 
5.0%; the inter-assay CV was less than 8.5%. The ter-
minal dilution of the anti-VP antibodies was 1:24,000. 
The sensitivity of this assay was 1.56 pg VP per tube 
and intra-assay CV (determined as for OT) was 3.3%; 
the inter-assay CV was 6.3%. 
Statistical evaluation of the results
All data are expressed as mean ± standard error of 
the mean (SEM). The significance of the differences 
between means was assessed by one-way analysis of 
variance (ANOVA), followed by the post-hoc Fisher 
test; p = 0.05 was considered as the minimal level of 
significance. STATISTICA (version 12) software (Stat-
Soft, Poland) was used for all calculations.
Results
8-Br-cAMP (i.e. cAMP analogue) significantly increased 
OT and VP secretion from the rat H-NH system in vitro 
when the explants were preincubated in the control 
medium (Figures 1A and 2A). This stimulatory effect 
was eliminated by preincubation of the explants with 
the medium enriched with PKA inhibitors, i.e. cAMPS-
-Rp (Figures 1B and 2B) or H-89 (Figures 1C and 2C). 
Under control conditions, 10–7 M melatonin, but not 
10–9 M melatonin, significantly diminished basal OT 
(Fig. 1A) and VP (Fig. 2A) output from the rat H-NH 
system and inhibited the cAMP analogue-stimulated 
secretion of OT and VP, at both concentrations studied 
(Figures 1A and 2A). Such effects of melatonin on the 
secretion of both neurohypophysial hormones could 
not be seen when the explants were first preincubated 
in the presence of cAMPS-Rp (Figures 1B and 2B). In 
contrast, melatonin did not influence the basal release 
of OT and VP after preincubation of the explants with 
H-89; however, treatment with both 8-Br-cAMP and 
melatonin, 10–7 M and 10–9 M, significantly reduced 
OT and VP secretion, compared to 8-Br-cAMP alone 
(Figures 1C and 2C).
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Figure 2. The influence of melatonin (MT), at the concentrations of 10–9 and 10–7 M, on the basal and cAMP analogue (8-Br-cAMP)- 
-dependent vasopressin (VP) release from the rat hypothalamo-neurohypophysial (H-NH) system in vitro, preincubated in normal K-R 
buffer (control) (A) or in the presence of PKA inhibitors — cAMPS-Rp (B) or H-89 (C). Each bar represents mean ± SEM; number of 
samples per group (n) = 6–8; *p < 0.05, **p < 0.01
Rycina 2. Wpływ melatoniny (MT), w stężeniach 10–9 i 10–7 M, na podstawowe i zależne od analogu cAMP (8-Br-cAMP) wydzielanie 
wazopresyny (VP) z układu podwzgórze–część nerwowa przysadki (H-NH) szczura in vitro, preinkubowanego w normalnym buforze 
K-R (kontrola) (A), bądź w obecności inhibitorów PKA — cAMPS-Rp (B) lub H-89 (C). Wyniki przedstawiają średnią ± SEM; liczba 
próbek w grupie (n) = 6–8; *p < 0.05, **p < 0.01
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Figure 1. The influence of melatonin (MT), at the concentrations of 10–9 and 10–7 M, on the basal and cAMP analogue (8-Br-cAMP)- 
-dependent oxytocin (OT) release from the rat hypothalamo-neurohypophysial (H-NH) system in vitro, preincubated in normal K-R 
buffer (control) (A) or in the presence of PKA inhibitors — cAMPS-Rp (B) or H-89 (C). Each bar represents mean ± SEM; number of 
samples per group (n) = 6–8; *p < 0.05, **p < 0.005, ***p < 0.00005
Rycina 1. Wpływ melatoniny (MT) w stężeniach 10–9 i 10–7 M na podstawowe i zależne od analogu cAMP (8-Br-cAMP) wydzielanie 
oksytocyny (OT) z układu podwzgórze–część nerwowa przysadki (H-NH) szczura in vitro, preinkubowanego w normalnym buforze 
K-R (kontrola) (A), bądź w obecności inhibitorów PKA — cAMPS-Rp (B) lub H-89 (C). Wyniki przedstawiają średnią ± SEM; liczba 
próbek w grupie (n) = 6–8; *p < 0.05, **p < 0.005, ***p < 0.00005
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Discussion
Our findings indicate that the cAMP analogue (8-Br- 
-cAMP) has a stimulatory role on OT and VP secretion 
from the rat hypothalamo-neurohypophysial (H-NH) 
system in vitro. This observation confirms that cAMP 
plays a significant role in the regulation of neurohypo-
physial hormone release and is in line with previous 
observations [16]. Additionally, by demonstrating the 
ability of potent PKA inhibitors to negate the stimula-
tory effect of 8-Br-cAMP on OT and VP output from the 
rat H-NH system in vitro, our findings confirm that ac-
tive PKA is a prerequisite for cAMP-mediated excitation 
of neurohypophysial hormone secretion.
Inactive PKA consists of two regulatory and two 
catalytic subunits. For PKA to be activated, two mole-
cules of cAMP bind to each regulatory subunit. This 
binding of cAMP molecules initiates the dissociation 
of two catalytic subunits from the regulatory subunits; 
these become catalytically active by binding adenosine 
triphosphate (ATP) and can then phosphorylate target 
substrate(s) [20, 38]. Several pharmacological inhibitors 
of PKA, which can easily cross cell membranes, have 
commonly been used to investigate the physiological 
functions of PKA, either individually or in combination. 
One such inhibitor is H-89, which has been found to act 
as a competitive antagonist of ATP at its binding site on 
the PKA catalytic subunits [20], and to offer great value 
in discriminating between the effects of PKA and other 
cAMP-regulated proteins such as EPACs. As a potent PKA 
inhibitor, H-89 has been found to abolish various effects 
of cAMP/PKA stimulation by forskolin, PACAP, or 8-Br-
cAMP in vitro [21, 24, 25, 28, 29]. However, H-89 has also 
been found to have a range of properties not asso ciated 
with PKA, and to restrain the activity of several kinases 
other than PKA, including protein kinase C (PKC), 
Rho-associated kinase (ROCK-II), extracellular signal-
regulated kinase 1 and 2 (ERK 1/2), mitogen-activated 
protein kinase (MAPK), mitogen- and stress-activated 
protein kinase 1 (MSK1), and ribosomal protein s6 
kinase (S6K1) [20, 39]. To provide more reliable results 
when studying the physiological functions of PKA, H-89 
is usually employed in combination with other PKA 
inhibitors and/or analogues. Hence, the present experi-
ment uses a combination of two PKA inhibitors: H-89 
and cAMPS-Rp, which acts as a competitive antagonist 
of PKA by interaction with cAMP binding sites on the 
regulatory subunits [19, 20]. Our findings show, for the 
first time, that both PKA inhibitors are capable of negat-
ing the stimulatory effect of cAMP analogue on OT and 
VP secretion from the rat H-NH system. This observa-
tion is in agreement with those of previous stu dies 
demonstrating the ability of H-89 and/or cAMPS-Rp 
to antagonise various effects of cAMP/PKA stimulators 
under a range of experimental conditions [25, 26, 28, 29]. 
For example, H-89 antagonised the effect of 8-Br-cAMP 
on epidermal growth factor (EGF)-induced ERK2 phos-
phorylation in primary cultures of rat hepatocytes [29], 
while in another study, 8-Br-cAMP and PACAP treat-
ment significantly increased nitric oxide synthase type 
1 (NOS1) level in rat pituitary gonadotrophs in vitro, 
and H-89 was able to inhibit such stimulation [25].
Previous studies strongly suggest that the inhibitory 
impact exerted by melatonin on OT and VP secretion 
from the rat H-NH system engages the cAMP-mediated 
mechanism(s) [18]. However, although it is likely that 
PKA is engaged in the intracellular cAMP-mediated sig-
nalling pathway in the melatonin-dependent inhibition 
of neurohypophysial hormone release, this remains to 
be demonstrated. Therefore, it was hypothesised in the 
present study that the cAMP/PKA signal transduction 
pathway is engaged in melatonin-dependent inhibition 
of OT and VP release. To demonstrate such media-
tion, cAMPS-Rp and H-89 were used, these being two 
PKA inhibitors with different mechanisms of action: 
cAMPS-Rp blocks the activity of both the regulatory 
and catalytic subunits of PKA, while H-89 mainly blocks 
the catalytic subunits. The obtained results confirm our 
hypothesis that the cAMP/PKA signal transduction 
pathway is engaged by melatonin to inhibit OT and VP 
output from the rat hypothalamo-neurohypophysial 
system; however, the precise mechanism of its action 
is more complicated and remains to be elucidated. Our 
present finding that cAMPS-Rp application completely 
blocks the effects of melatonin on OT and VP secretion 
suggests that the regulatory subunits of PKA need to be 
active to allow melatonin to exert its inhibitory effect 
on the basal and cAMP analogue-stimulated secretion 
of the neurohypophysial hormones. In mammals, an 
existence of two classes of regulatory subunits (RI and 
RII) and two subtypes (α and β) in each class deter-
mine a basis for classification of four PKA isoenzymes: 
RIα, RIβ, RIIα, and RIIβ [40], which play a crucial role 
in neuronal functions and are distributed in different 
brain regions [41]. In the mouse brain, the map of the 
intracellular distribution of PKA regulatory subunits 
shows that in the neuron, subunit RIβ is present in cell 
bodies and dendrites, whereas subunit RIIβ is more 
concentrated in the axons [41]. As explants containing 
both cell bodies, where OT and VP are synthesised, as 
well as the axons of oxytocinergic and vasopressinergic 
neurons, were used in the present in vitro experiment, 
it may suggest that activated by melatonin the cAMP/ 
/PKA-mediated pathway is engaged in the modifica-
tion of synthesis, axonal transport, and/or secretion of 
the neurohypophysial hormones. In addition, because 
melatonin, acting via the MT1 receptor, participates in 
cAMP/PKA-dependent inhibition of the nuclear factor 
565
Endokrynologia Polska 2018; 69 (5)
PR
A
C
E 
O
RY
G
IN
A
LN
E
CREB phosphorylation [2, 3, 9], and CREB was found 
to play a role in cAMP-mediated regulation of VP gene 
transcription in the rat hypothalamus [17], it is pos-
sible that nuclear factor CREB may be involved in the 
melatonin-dependent cAMP/PKA-mediated inhibition 
of OT and VP synthesis and/or secretion from the rat 
H-NH system. This, however, remains to be demon-
strated and does not exclude the participation of other 
transcription factors and/or other mechanisms.
Namely, H-89 was able to block the effect of mela-
tonin on the basal secretion of OT and VP, but it did not 
interfere with the inhibitory action of melatonin on their 
release in the presence of the cAMP analogue in the 
medium. Therefore, it should be considered that mela-
tonin may exert an influence on OT and VP release by 
cAMP-mediated mechanisms other than the cAMP/PKA 
signalling pathway. As mentioned above, H-89 inhibits 
the activity of several protein kinases and has various 
non-PKA-based effects. In addition, melatonin is known 
to act by modulating signal transduction cascades medi-
ated by various kinases other than PKA, such as MAPK, 
ERK1/2, and PKC [42–45]. Melatonin, acting via the MT1 
receptor, and the cAMP-mediated pathways may also 
elicit signalling responses involving the regulation of 
chloride, sodium, potassium, or calcium fluxes and of 
specific ion channels, such as cAMP-mediated phos-
phorylation of calcium-activated potassium channels 
(BKCa), voltage-dependent calcium channels (VDCC), 
or inward-rectifier potassium channels (Kir), depend-
ing on the cell type [2, 46]. For example, melatonin is 
thought to inhibit the neuronal firing in the SCN by the 
activation of Kir3 channels [2]. Melatonin is also able to 
affect the production of reactive oxygen species, among 
others nitric oxide [47], while the cAMP/PKA signalling 
pathway has been found to induce the expression of 
NOS1 in rat pituitary cells in vitro [28]. In this context, 
it should be mentioned that together with various 
ions, e.g. potassium and calcium, nitric oxide [48] plays 
a significant role in the neurosecretory function of mag-
nocellular neurons [5, 49, 50]. Therefore, it is possible 
that in the current study, under the conditions of PKA 
catalytic subunits blockade by H-89, melatonin might 
employ an alternate route to inhibit cAMP analogue-
dependent OT and VP output from the rat H-NH sys-
tem. Moreover, the explant used for our present in vitro 
study was isolated from other brain regions, which in 
normal conditions deliver excitatory and/or inhibitory 
afferent signals, through several neuromediators and 
neuromodulators, to the magnocellular nuclei [49–51]. 
The lack of such signals could hide or modify the effect 
of melatonin on neurohypophysial hormone release 
through the cAMP/PKA signalling pathway.
In conclusion, our results show, for the first 
time, that melatonin employs the cAMP/PKA signal 
transduction pathway to inhibit OT and VP secre-
tion from the rat hypothalamo-neurohypophysial 
system. However, other cAMP-mediated mechanisms 
are not excluded from this process and future stud-
ies are needed to determine which of them, possibly 
including the contribution of transcription factors, 
are responsible for the inhibitory influence of mela-
tonin on neurohypophysial hormone synthesis and/ 
/or secretion. 
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